Findings

What do systematic reviews say?

4,760 questions · 8,065 findings · 1,036 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,686 · 20.9%GRADE not reported 675 · 8.4%Very low 1,953 · 24.2%Low 2,048 · 25.4%Moderate 1,296 · 16.1%High 407 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Effect of low‐dose alcohol vs placebo

Systolic blood pressure · adult participants

1 finding from 1 review

Effect of alcohol on blood pressure 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
Low

Effect of low‐dose alcohol vs placebo

Diastolic blood pressure · adult participants

1 finding from 1 review

Effect of alcohol on blood pressure 2020 · Cochrane Headline outcomes only
no estimate extracted
28 participants
Low

Effect of low‐dose alcohol vs placebo

Heart rate · adult participants

1 finding from 1 review

Effect of alcohol on blood pressure 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
Moderate

Low molecular weight heparin vs no prophylaxis

PE: assessed by CT arteriography ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in PE: assessed by CT arteriography ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.81 [0.49, 6.65]
3 studies · 1820 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Symptomatic DVT · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.61 [0.18, 2.03]
4 studies · 1848 participants
Low

Low molecular weight heparin vs no prophylaxis

Asymptomatic DVT · adults undergoing KA

It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.14 [0.03, 0.61]
2 studies · 369 participants
Very low

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.85 [0.95, 3.59]
5 studies · 1978 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Major bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.98 [0.06, 15.72]
1 study · 1451 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Minor bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.79 [0.84, 3.84]
5 studies · 1978 participants
Moderate

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic PE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.6 [0.42, 0.88]
8 studies · 5324 participants
Moderate

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.48 [0.35, 0.67]
9 studies · 5408 participants
High

Low molecular weight heparin vs no thromboprophylaxis

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.57 [0.46, 0.71]
10 studies · 5743 participants
High

Low molecular weight heparin vs no thromboprophylaxis

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.94 [0.83, 1.07]
9 studies · 2681 participants
Low

Low molecular weight heparin vs no thromboprophylaxis

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 3.4 [1.2, 9.63]
4 studies · 3105 participants
Moderate

Low molecular weight heparin vs active control

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High

Low molecular weight heparin vs active control

Major bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.76]
2 studies · 781 participants
Low
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs active control

Symptomatic PE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 2.89 [0.12, 66.75]
Studies not reported
GRADE not reported
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.13 [0.02, 1.03]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.11 [0.01, 2.06]
1 study · 439 participants
Low

Low molecular weight heparin vs active control

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.81 [0.32, 2.04]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.43 [0.17, 1.1]
1 study · 439 participants
Moderate

Low molecular weight heparin vs active control

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found